Kidney Disease,” an editorially independent special report that was produced with financial support from Vertex. M ore than ...

The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification ...

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention. Now, a study ...

Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ecnoglutide, with potential payments ​of up to $495 million if milestones are ‌met, the Chinese drugmaker said ...

Preclinical studies in animals have already shown that GLP-1 drugs can reduce reward-seeking behavior. Early clinical work in humans has begun to hint at similar effects. A randomized trial of ...

Semaglutide patent in India expires in March 2026, enabling over 50 branded generic versions to enter the market, likely ...

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...